Successful treatment of primary cardiac lymphoma with monoclonal CD20 antibody (rituximab).
Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma.
Nakagawa
Yukinori
Y
Division of Cardiovascular Medicine, Jichi Medical School, Tochigi, Japan.
Ikeda
Uichi
U
Hirose
Masahiro
M
Ubukata
Satoshi
S
Katsuki
Taka-Aki
TA
Kaminishi
Yuichiro
Y
Saito
Tsutomu
T
Hironaka
Mitsugu
M
Izumi
Tohru
T
Shimada
Kazuyuki
K
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005710:Gallium Radioisotopes; D006338:Heart Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D011877:Radionuclide Imaging; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005710:Gallium Radioisotopes; D000069283:Rituximab